dc.creator | Karanikas, V. | en |
dc.creator | Soukou, F. | en |
dc.creator | Kalala, F. | en |
dc.creator | Kerenidi, T. | en |
dc.creator | Grammoustianou, E. S. | en |
dc.creator | Gourgoulianis, K. I. | en |
dc.creator | Germenis, A. E. | en |
dc.date.accessioned | 2015-11-23T10:33:20Z | |
dc.date.available | 2015-11-23T10:33:20Z | |
dc.date.issued | 2008 | |
dc.identifier | 10.1016/j.clim.2008.07.024 | |
dc.identifier.issn | 15216616 | |
dc.identifier.uri | http://hdl.handle.net/11615/29050 | |
dc.description.abstract | Survivin and its variant survivin-2B have been considered as potential candidates for cancer immunotherapy. The magnitude however of spontaneously occurring CD8+ T cells circulating precursor CTLs (pCTL), has never been evaluated. We set out to measure in 20 patients with lung carcinomas and 5 aged matched healthy male individuals (expressing HLA-A2 and/or -A24), the frequency of pCTLs specific for two naturally processed and presented peptides of survivin (LTLGEFLKL presented by HLA-A2) and survivin-2B (AYACNTSTL presented by HLA-A24) since these peptides are the only ones used in immunotherapeutic trials. The frequency of peptide-specific pCTLs was estimated using a sensitive method that combines HLA-multimer flow cytometric technology with a previous step of in vitro amplification under limiting dilution conditions. Anti-survivin or anti-survivin-2B specific CTL clones were not detected in 17 out of the 21 tested patients, and in none of the healthy individuals. In a number of peripheral blood mononuclear cell microcultures of the remaining 4 patients, diffuse clusters stained weakly by the HLA-multimers were observed which were not amplified after further stimulation and, therefore, they were finally considered as negative. The significance of the levels of spontaneously occurring CTL-responses against survivin and survivin-2B peptides, in cancer patients and cancer-free subjects, remains to be elucidated and it would be interesting to be considered in relation to the clinical efficacy of anti-cancer vaccination protocols. © 2008 Elsevier Inc. All rights reserved. | en |
dc.source | Clinical Immunology | en |
dc.source.uri | http://www.scopus.com/inward/record.url?eid=2-s2.0-53949108094&partnerID=40&md5=70e37c3ee1a350d629e61292c6590985 | |
dc.subject | HLA-multimers | en |
dc.subject | Peptide-specific CD8+ T cells | en |
dc.subject | Spontaneously occurring CD8+ T-cell responses | en |
dc.subject | Survivin | en |
dc.subject | Survivin-2B | en |
dc.subject | HLA A2 antigen | en |
dc.subject | HLA A24 antigen | en |
dc.subject | survivin 2b | en |
dc.subject | unclassified drug | en |
dc.subject | adult | en |
dc.subject | aged | en |
dc.subject | article | en |
dc.subject | CD8+ T lymphocyte | en |
dc.subject | cell culture | en |
dc.subject | clinical article | en |
dc.subject | controlled study | en |
dc.subject | female | en |
dc.subject | flow cytometry | en |
dc.subject | human | en |
dc.subject | human cell | en |
dc.subject | lung carcinoma | en |
dc.subject | male | en |
dc.subject | molecular cloning | en |
dc.subject | peripheral blood mononuclear cell | en |
dc.subject | priority journal | en |
dc.subject | protein expression | en |
dc.subject | protein variant | en |
dc.subject | Antigens, Neoplasm | en |
dc.subject | Humans | en |
dc.subject | Interferon Type II | en |
dc.subject | Lung Neoplasms | en |
dc.subject | Microtubule-Associated Proteins | en |
dc.subject | Middle Aged | en |
dc.subject | Neoplasm Proteins | en |
dc.subject | Polymerase Chain Reaction | en |
dc.subject | T-Lymphocytes, Cytotoxic | en |
dc.title | Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals | en |
dc.type | journalArticle | en |